Cineverse Corp. filings document material events, capital-structure actions and governance matters for an entertainment technology company and studio listed on Nasdaq under its Class A common stock. Recent 8-K disclosures cover material agreements, registered equity-offering activity, preferred-stock exchange arrangements, and other transactions affecting the company’s common and preferred securities.
The company’s regulatory record also includes disclosures on executive officer changes, employment arrangements, equity incentive plan amendments, annual meeting votes and acquisition-related material events. These filings provide formal reporting on Cineverse’s governance, shareholder approvals, security structure and corporate actions alongside its operating and financial-result disclosure categories.
Cineverse Corp. reported that it has entered into a new employment agreement with Mark Lindsey, effective as of September 14, 2025, under which he will continue to serve as the Company’s Chief Financial Officer through a term ending September 13, 2027, with automatic one-year renewals unless timely notice is given.
The agreement provides Mr. Lindsey with an annual base salary of $350,000, a target bonus opportunity of $175,000 under the Company’s Management Annual Incentive Plan, and restricted stock units for 71,699 shares of common stock under the 2017 Equity Incentive Plan, along with participation in standard senior executive benefit plans.
Upon a termination without cause or a resignation for good reason, Mr. Lindsey is entitled to 12 months of base salary, and if such a termination occurs within two years after a change in control during the term, he would instead receive a lump-sum payment equal to two times his then-current base salary plus his target bonus for the year of termination.
Mark W. Lindsey, CFO of Cineverse Corp. (CNVS), reported changes in his beneficial ownership on Form 4. The filing shows a disposition of 119,168 shares of Class A common stock on 09/23/2025. It also reports outstanding equity awards: a Stock Appreciation Right exercisable at $11.95 covering 20,000 underlying shares expiring 11/14/2032, and multiple Restricted Stock Units (RSUs) totaling 138,366 RSUs across different grant schedules that vest between 2025 and 2028. Specific vesting schedules are included for each award.
The company disclosed select 10-Q details for the quarter ended June 30, 2025. Its Line of Credit bears interest at 1.25% above prime, equal to 8.75% as of June 30, 2025, and matures April 8, 2028. $3.6 million was outstanding on that facility as of June 30, 2025, with $168 thousand of unamortized issuance costs recorded as other long-term assets. The company recorded a $206 thousand cost-method investment in Roundtable Securities, paid by issuing 16 thousand shares of common stock; the investment is carried at cost because ownership is under 20% and the company does not exert significant influence. No impairment charges on long-lived or finite-lived intangible assets were recorded for the three months ended June 30, 2025 and 2024. Share authorization and outstanding figures are provided for common stock and preferred series in the filing text.
Cineverse Corp. furnished an update that it has released its financial results for the three months ended June 30, 2025. The company announced these quarterly figures through a press release dated August 14, 2025, which is attached as an exhibit to the report. The earnings information in the press release and this section is designated as furnished, not filed, under securities laws, which affects how it is treated for certain liability purposes.
Cineverse (NASDAQ:CNVS) filed a Form 8-K on June 27, 2025.
The sole disclosure (Item 2.02) states the company issued a press release announcing financial results for the three- and twelve-month periods ended March 31, 2025. The press release is furnished as Exhibit 99.1 and is deemed "furnished" rather than "filed," limiting Exchange Act liability and incorporation by reference.
No financial figures, guidance, or qualitative commentary are included in the body of the 8-K; therefore, investors must review Exhibit 99.1 for details.